Synta Announces Presentation of Ganetespib Phase 2 Non-small Cell Lung Cancer Trial Results

Synta Pharmaceuticals Corp. SNTA today presented results at the International Association for the Study of Lung Cancer 14th World Conference on Lung Cancer from a Phase 2 single agent clinical trial of ganetespib in advanced non-small cell lung cancer that showed promising clinical activity in patients with progressive disease. Ganetespib is a potent inhibitor of heat shock protein 90 (Hsp90) currently being studied in a broad range of clinical trials with approximately 400 patients treated to date. Ganetespib is structurally unrelated to first-generation, ansamycin-family Hsp90 inhibitors such as 17-AAG or IPI-504.